从“突破”到“破局”,看君圣泰如何搅动千亿代谢市场

格隆汇
21 Jul

在2025年美国糖尿病协会(ADA)科学年会的聚光灯下,"最新突破性专场"报告迎来了一位中国面孔——君圣泰医药(2511.HK)。该公司报告了其核心产品HTD1801治疗2型糖尿病(T2DM)的关键临床III期SYMPHONY 1研究数据,这不仅标志着中国源头创新药获得国际顶级学术平台的高度认可,也为其“一药多效”的创新理念提供了强有力的科学背书。值得注意的是,资本市场同样传递出积极信号,展现出来...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10